Business models in pharmaceutical industry
Business Breakfast dedicated to Evolution of Business Models in Pharmaceutical Industry took place at Roland Berger office in Warsaw on 20th of June. The meeting was headed by Aleksander Ruzicic (an expert of Roland Berger International Competence Center Pharma & Helthcare), and Maciej Korzeniowski (Director at Warsaw Roland Berger Office). Our guests were Board Members and Marketing and Sales Directors representing leading pharmaceutical companies in Poland.
During Business Breakfast we presented results of international study conducted by Roland Berger experts this year. The study focused on changes, which take place in the world biggest pharmaceutical concerns, and which concern commercial side of their activity - that is business models of sales and marketing of medicines.
The traditional business model of pharmaceutical industry is not able to face up the nowadays difficult operating conditions of companies, such as unpredictable lead times of new products, growing costs of sales and marketing as well as increasing demands of clients and governments. To meet the expectations of shareholders, companies have to consider introducing significant changes into their approach to the clients, products as well as sales activities. Roland Berger consultants created a tool, which facilitates designing of such changes and enables to determine key features of new business model.
Discussion that took place after presentation shown, that challenges of pharmaceutical business in Poland do not diverge from situation in Western Europe. Polish managers ask themselves the same questions as their Western counterparts, however the answers always have to be adapted to market and company-specific conditions.
Contact Grzegorz Łaptaś for more information about results of the study and concept of Commercial Excellence in pharmaceutical industry:
During Business Breakfast we presented results of international study conducted by Roland Berger experts this year. The study focused on changes, which take place in the world biggest pharmaceutical concerns, and which concern commercial side of their activity - that is business models of sales and marketing of medicines.
The traditional business model of pharmaceutical industry is not able to face up the nowadays difficult operating conditions of companies, such as unpredictable lead times of new products, growing costs of sales and marketing as well as increasing demands of clients and governments. To meet the expectations of shareholders, companies have to consider introducing significant changes into their approach to the clients, products as well as sales activities. Roland Berger consultants created a tool, which facilitates designing of such changes and enables to determine key features of new business model.
Discussion that took place after presentation shown, that challenges of pharmaceutical business in Poland do not diverge from situation in Western Europe. Polish managers ask themselves the same questions as their Western counterparts, however the answers always have to be adapted to market and company-specific conditions.
Contact Grzegorz Łaptaś for more information about results of the study and concept of Commercial Excellence in pharmaceutical industry:
